Last reviewed · How we verify
NCT03857958
Metal Versus Plastic Stent in Malignant Hilar Biliary Obstruction
NA trial testing endoscopic retrograde cholangio-pancreatography in Malignant Hepatobiliary Neoplasm in 54 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 54 |
| Start date | 15 February 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- endoscopic retrograde cholangio-pancreatography
Conditions studied
- Malignant Hepatobiliary Neoplasm — all drugs for Malignant Hepatobiliary Neoplasm →
Sponsor
Seoul National University Hospital
Who can join
19 and older, any sex, with Malignant Hepatobiliary Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to compare the difference in the stent patency duration between side-by-side fully covered self-expanding metal stents (SEMS) and side-by-side plastic stents in patients with malignant hilar biliary obstruction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Side-by-side placement of fully covered metal stents versus conventional 7F plastic stents in malignant hilar biliary obstruction: Prospective randomized controlled trial.
Paik WH, Jung MK, Kim DU, Song TJ, et al · · 2024 · cited 8× · PMID 37612129 · DOI 10.1111/den.14669
Verify or expand the search:
- PubMed search for NCT03857958
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Hepatobiliary Neoplasm
Currently open trials in the same condition.
- NCT07124546 — Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancer · NA · recruiting
- NCT06053333 — Social Determinants of Health in Hepatobiliary Cancer Patients · recruiting
- NCT05334069 — Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection · recruiting
- NCT04704661 — Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expre · Phase 1 · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03857958 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 4 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03857958.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing